{
    "name": "nitazoxanide",
    "comment": "Rx",
    "other_names": [
        "Alinia"
    ],
    "classes": [
        "Antiparasitic Agents"
    ],
    "source": "https://reference.medscape.com/drug/alinia-nitazoxanide-342664",
    "pregnancy": {
        "common": [
            "No data with pregnant women to inform of drug-associated risk; No teratogenicity or fetotoxicity observed in animal reproduction studies with administration of nitazoxanide to pregnant rats and rabbits during organogenesis at exposures 30 and 2 times, respectively, the exposure at maximum recommended human dose of 500 mg twice daily based on body surface area (BSA)"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Development and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Safety and efficacy not established in HIV+ or immunodeficient patients",
                "Effects in hepatic/renal impairment unknown; use caution",
                "Safety and efficacy of suspension in children <1 year not established",
                "Safety and efficacy of tablets in children <12 years not established"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Tizoxanide (active metabolite of nitazoxanide) is highly bound to plasma protein (>99.9%)",
                        "Monitor for adverse reactions if nitazoxanide is coadministered with other highly protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (eg, warfarin)",
                        "The prescribing information recommends avoiding concurrent warfarin use"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "nitazoxanide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baricitinib",
            "description": {
                "common": "nitazoxanide will increase the level or effect of baricitinib by  decreasing elimination. Avoid or Use Alternate Drug. Coadministration of baricitinib with strong organic anion transporter 3 (OAT3) inhibitors is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "nitazoxanide, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "nitazoxanide, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "nitazoxanide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "nitazoxanide, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "nitazoxanide, phenytoin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "nitazoxanide, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valproic acid",
            "description": {
                "common": "nitazoxanide, valproic acid.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "nitazoxanide, acetazolamide.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acitretin",
            "description": {
                "common": "nitazoxanide, acitretin.\nEither increases levels of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "nitazoxanide, aspirin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bumetanide",
            "description": {
                "common": "nitazoxanide, bumetanide.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "nitazoxanide, chlorthalidone.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "nitazoxanide, cisplatin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clindamycin",
            "description": {
                "common": "nitazoxanide, clindamycin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "nitazoxanide, glipizide.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "nitazoxanide, glyburide.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "nitazoxanide, tacrolimus.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vincristine",
            "description": {
                "common": "nitazoxanide, vincristine.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dicloxacillin",
            "description": {
                "common": "nitazoxanide, dicloxacillin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "nitazoxanide, diphenhydramine.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "nitazoxanide, fenoprofen.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indomethacin",
            "description": {
                "common": "nitazoxanide, indomethacin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "nitazoxanide, meclofenamate.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "nitazoxanide, mefenamic acid.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "naproxen",
            "description": {
                "common": "nitazoxanide, naproxen.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ospemifene",
            "description": {
                "common": "nitazoxanide, ospemifene.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "piroxicam",
            "description": {
                "common": "nitazoxanide, piroxicam.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "spironolactone",
            "description": {
                "common": "nitazoxanide, spironolactone.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "nitazoxanide, sulfamethoxazole.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulindac",
            "description": {
                "common": "nitazoxanide, sulindac.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "nitazoxanide, tolbutamide.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolmetin",
            "description": {
                "common": "nitazoxanide, tolmetin.\nEither increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "1"
        },
        {
            "name": "Abdominal pain",
            "percent": "8"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Chromaturia",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "1"
        },
        {
            "name": "Increased ALT",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Appetite increased",
            "percent": null
        },
        {
            "name": "Creatinine increased",
            "percent": null
        },
        {
            "name": "Diaphoresis",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Eye discoloration",
            "percent": null
        },
        {
            "name": "pale yellow",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Infection",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Thinitis",
            "percent": null
        },
        {
            "name": "Salivary glands enlarged",
            "percent": null
        },
        {
            "name": "Urine discoloration",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "gastroesophageal reflux disease",
            "percent": null
        },
        {
            "name": "Nervous System disorders",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic and mediastinal disorders",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "urticarial",
            "percent": null
        }
    ]
}